Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0020538 (
hypertension
)
170,190
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Blood pressure is low at birth. It increases with age by about 1 mm Hg per day within the period of 3-8 days. It rises by about 1 mm Hg per week between 5 and 6 weeks of age.
Neonatal hypertension
carries a risk of cardiorespiratory failure and cerebral distress. Causes of neonatal
hypertension
are either secondary to congenital malformations or to acquired disease states. Congenital etiologies include: renal artery stenosis, renal artery hypoplasia, abdominal aortic atresia, coarctation of the aorta, kidney cystic disease, reflux nephropathies. Acquired causes include: thrombo-embolic renal artery complications secondary to umbilical artery catheterization or to thrombosis of the ductus arteriosus, closure of abdominal wall defects, adrenal hematoma with renal artery compression, seizures in preterm infants, central nervous system disorders, drug-induced
hypertension
, infants of drug-dependent mothers. The morbidity and the mortality of neonatal
hypertension
are elevated. Death may be caused by severe uncontrollable
hypertension
or by concomitant problems. Morbidity may be related to drug-resistant
hypertension
, or to the side-effects of hypotensive drugs.
...
PMID:Arterial hypertension in the newborn infant. 265 Jul 49
Neonatal hypertension
, defined as systolic blood pressure greater than 95th percentile for age, size, and gender, is an uncommon but significant problem.
Hypertension
may develop secondary to thromboembolic complications of central lines, steroid use, or be a sign of an underlying renal or cardiac problem. Pharmacologic management of
hypertension
in the neonate includes use of beta blockers, angiotensin-converting enzyme inhibitors, calcium channel blockers, and/or diuretics. This article discusses issues in assessment and management of neonatal
hypertension
and reviews the pharmacologic agents most commonly utilized in the neonatal setting.
...
PMID:Hypertension in neonates causes and treatments. 1266 40
Neonatal hypertension
occurs in 2% of all infants and it is caused by renovascular abnormalities in 70% of these infants. The gold standard for diagnosing renovascular disease is conventional renal angiography. However, in neonates the procedure is not commonly used because of its invasive and technically challenging nature. MRI and MR angiography (MRA) are less invasive yet reliable means of detecting renovascular disease in adults. There is minimal literature on the use of MRI/MRA in neonatal
hypertension
. We report a neonate with
hypertension
secondary to a renovascular abnormality in which MRI/MRA was helpful in uncovering segmental renal artery stenosis. The infant underwent partial nephrectomy with subsequent resolution of his
hypertension
. Further studies are needed to validate the use of MRI/MRA in the evaluation of neonatal
hypertension
.
...
PMID:MR angiography in the evaluation of a renovascular cause of neonatal hypertension. 1632 26
There has been a temporal trend towards increased birth weight over the past three decades. This increase in birth weight may have resulted in an increase in neonatal blood pressure.
Neonatal hypertension
is becoming more common, especially in neonatal intensive care unit survivors. Current normative values are required to assist in diagnosis and appropriate management of neonatal hypotension and
hypertension
. The objective of this study was to determine normative blood pressure readings in healthy term neonates. Term neonates from the postnatal ward were enrolled from August 2003 to August 2005. Exclusion criteria included infants of mothers with preeclampsia,
hypertension
of any cause, gestational diabetes, type 1 diabetes mellitus and illicit substance use, infant congenital or chromosomal anomaly, admission to the neonatal intensive care unit or possible sepsis. Of the 406 infants enrolled, 218 were male. The median systolic, diastolic and mean blood pressures on day 1 of life were 65 mmHg, 45 mmHg, and 48 mmHg, respectively. On day 4, these values had increased to 70 mmHg, 46 mmHg and 54 mmHg. There was a significant elevation in blood pressure from day 1 to day 2 of life. There was no significant difference in blood pressure readings with respect to birth weight or length. The only significant difference between the sexes was a lower mean and diastolic pressure on day 2 in boys. This study has provided current normative blood pressure readings of healthy term neonates that can be used to assess both hypotension and
hypertension
in the term neonate. No increase in blood pressure was noted from previous studies.
...
PMID:Normative blood pressure data in the early neonatal period. 1743 31
Neonatal hypertension
occurs in up to 2% of neonatal intensive care survivors and in up to 3% of all neonates. Normal blood pressure (BP) measurements are required to diagnose and manage appropriately both hypotension and
hypertension
in the neonate and infant. The aim of this study was to provide normative BP measurements during the first year of life of healthy infants born at term, using an oscillometric method. Neonates were enrolled from August 2003 to August 2005. Exclusion criteria included: infants of mothers with
hypertension
or diabetes of any type, use of illicit substances, congenital or chromosomal anomaly, admission to the neonatal intensive care unit or possible sepsis. There were 406 infants enrolled, with 150 children followed at 6 months of age and 118 children at 12 months of age. There were no differences in BP measurements at 6 months or 12 months of age by gender, weight or height. A BP measurement above the 90th percentile on day 2 or at 6 months was not predictive of a BP above the 90th percentile at 12 months of age. Higher systolic and diastolic measurements at 6 months and 12 months were found, in comparison to those in previous studies using ultrasonic devices. The findings of this study provide normative BP values for infants during their first year of life, using the oscillometric method, the most frequently used method in paediatric, neonatal intensive care and emergency departments.
...
PMID:Blood pressure in the first year of life in healthy infants born at term. 1768 Feb 75
Neonatal hypertension
is an uncommon but important complication of intensive care management. The aims of this study were to identify in neonates with
hypertension
: antenatal and postnatal risk factors; aldosterone and renin levels; and report on outcome in early infancy. The study involved a retrospective review of neonates diagnosed with
systemic hypertension
from January 2001 to December 2005. Demographic data, risk factors, laboratory investigation, and follow-up data at 3-6 months of age were collected. Of the 2,572 newborn infants included, 34 (1.3%) had neonatal
hypertension
. Gestational age and birth weight and length were significantly lower in infants with
hypertension
. The median postnatal age at diagnosis of
systemic hypertension
was 5.0 days. Antenatal steroid administration, maternal
hypertension
, umbilical arterial catheter, postnatal acute renal failure, patent ductus arteriosus, indomethacin treatment and chronic lung disease were associated with the development of neonatal
hypertension
[odds ratios (OR) 8.7, 3.8, 10.0, 51.8, 5.9, 5.7 and 7.7, respectively]. Elevated aldosterone and renin levels occurred in 60% and 33% but had normalised in the majority by 6 months of age. The majority of infants do not require treatment for
hypertension
by 6 months of age.
...
PMID:Antenatal and postnatal risk factors for neonatal hypertension and infant follow-up. 1787 36
Neonatal hypertension
is becoming a more common diagnosis because of higher survival rates in premature infants and the need for intravascular access and invasive blood pressure (BP) monitoring. Defining
hypertension
in the neonatal population has been challenging, and understanding what constitutes a normal BP is still evolving.Five general classes of antihypertensives exist for the treatment of
hypertension
in neonates. Few studies are available to guide clinicians in the treatment of
hypertension
in neonates, and limited data exist regarding outcomes of
hypertension
in the neonatal period.
...
PMID:A review of drug therapy for neonatal hypertension. 2458 1
Neonatal hypertension
(HT) is a frequently under reported condition and is seen uncommonly in the intensive care unit. Neonatal HT has defined arbitrarily as blood pressure more than 2 standard deviations above the base as per the age or defined as systolic BP more than 95% for infants of similar size, gestational age and postnatal age. It has been diagnosed long back but still is the least studied field in neonatology. There is still lack of universally accepted normotensive data for neonates as per gestational age, weight and post-natal age. Neonatal HT is an important morbidity that needs timely detection and appropriate management, as it can lead to devastating short-term effect on various organs and also poor long-term adverse outcomes. There is no consensus yet about the treatment guidelines and majority of treatment protocols are based on the expert opinion. Neonate with HT should be evaluated in detail starting from antenatal, perinatal, post-natal history, and drug intake by neonate and mother. This review article covers multiple aspects of neonatal
hypertension
like definition, normotensive data, various etiologies and methods of BP measurement, clinical features, diagnosis and management.
...
PMID:Neonatal hypertension. 2707 62
Neonatal hypertension
is increasingly recognized as dramatic improvements in neonatal intensive care, advancements in our understanding of neonatal physiology, and implementation of new therapies have led to improved survival of premature infants. A variety of factors appear to be important in determining blood pressure in neonates, including gestational age, birth weight, and postmenstrual age. Normative data on neonatal blood pressure values remain limited. The cause of
hypertension
in an affected neonate is often identified with careful diagnostic evaluation, with the most common causes being umbilical catheter-associated thrombosis, renal parenchymal disease, and chronic lung disease. Clinical expertise may need to be relied upon to decide the best approach to treatment in such patients, as data on the use of antihypertensive medications in this age group are extremely limited. Available data suggest that long-term outcomes are usually good, with resolution of
hypertension
in most infants. In this review, we will take a case-based approach to illustrate these concepts and to point out important evidence gaps that need to be addressed so that management of neonatal
hypertension
may be improved.
...
PMID:Neonatal hypertension: cases, causes, and clinical approach. 3125 Feb 5
Neonatal hypertension
is a rare but well recognised condition, especially in newborns needing invasive monitoring in the intensive care unit. Recognition of newborns with
hypertension
remains challenging because of natural variability in blood pressure with postconceptional age and the lack of reference data for different gestational ages. Investigation of neonates with
hypertension
can be challenging in light of the myriad differing aetiologies. This may be simplified by a systematic approach to investigation. There remains a relative paucity of data to guide the use of pharmacological therapies for
hypertension
in neonates. Clinicians rely on empirical management protocols based on experience and expert opinion. Much of the information on dosing regimens and protocols has simply been derived from the use of antihypertensive agents in older children and in adults, despite fundamental pathophysiological differences.
...
PMID:Fifteen-minute consultation: Neonatal hypertension. 3321 39
1